Zebrafish Cytochrome P450 Assays for Assessing Drug Metabolism and Drug Safety

Information

  • Research Project
  • 7393512
  • ApplicationId
    7393512
  • Core Project Number
    R43GM083366
  • Full Project Number
    1R43GM083366-01
  • Serial Number
    83366
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    4/1/2008 - 16 years ago
  • Project End Date
    11/30/2008 - 16 years ago
  • Program Officer Name
    HEART, LUNG, AND BLOOD INST., NATIONAL
  • Budget Start Date
    4/1/2008 - 16 years ago
  • Budget End Date
    11/30/2008 - 16 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/1/2008 - 16 years ago

Zebrafish Cytochrome P450 Assays for Assessing Drug Metabolism and Drug Safety

[unreadable] DESCRIPTION (provided by applicant): Cytochrome P450 (CYP) enzymes catalyze the majority of known drug metabolism and the bulk of these reactions occur in the liver. As a consequence, many clinically relevant drug-drug interactions are associated with inhibition and/or induction of a specific CYP enzyme. Modifications of CYP activities can have profound effects on therapeutic efficacy and can lead to life-threatening toxicity. In order to provide an early warning system for potential serious side effects, detection of specific CYPs responsible for drug metabolism and drug-drug interactions is a goal of all pre-clinical studies. An ideal CYP assay should be rapid, robust, reliable, reproducible, and amenable to automation in multiwell plate formats. This research will develop a microplate format high throughput whole zebrafish CYP functional assay for assessing drug metabolism and drug safety. Based on genetic and physiological similarity to humans, zebrafish show promise as an efficient, predictive animal model for assessing drug metabolism and drug safety. [unreadable] [unreadable] The zebrafish assay will facilitate detection of specific cytochromes responsible for drug metabolism and drug-drug interactions, and provide an early warning system for potential serious side effects, [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    160671
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:160671\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYLONIX PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES